Results 221 to 230 of about 122,763 (282)
Left bundle branch block-induced pseudo-infarction: Cardiac MRI pitfall. [PDF]
Flynn S, Killick D, McDonald K, Dodd J.
europepmc +1 more source
PDAC has a poor prognosis due to chemoresistance. We revealed that MCU upregulation is associated with chemoresistance and stemness in PDAC. MCU‐mediated Ca2+ influx induced ER stress, activating the PERK‐ATF4/NRF2 axis to enhance PSAT1/SLC711 expression and glutathione synthesis, reducing ROS and maintaining stemness.
Zekun Li +17 more
wiley +1 more source
Mutant p.Val114Ala Transthyretin-Related Cardiac Amyloidosis with Heart Failure and Right Bundle Branch Block. [PDF]
Murat S +7 more
europepmc +1 more source
Astrocyte Enrichment of 3D Cortical Constructs Enhances Brain Repair
This study highlights the role of astrocytes in supporting neural progenitor cell survival and differentiation after traumatic brain injury. Astrocytes enhanced neuronal differentiation, improved cell survival in co‐cultures, and promoted integration of microfluidics‐based implants with host tissue following implantation. Additionally, increased axonal
Elisa M. Cruz +20 more
wiley +1 more source
New electrocardiographic insights into left bundle branch block and the heart's electrical position: Case series. [PDF]
Robledo-Nolasco R +2 more
europepmc +1 more source
Dynamics of the Mammalian Placental Metabolome in Placentogenesis and Embryonic Development
This study identifies three metabolic stages (E8.5, E9.5–10.5, E11.5–14.5) and two transition periods (E8.5–9.5, E10.5–11.5) in mouse placental development. NAD(H) emerges as a key dynamic metabolite that enhances embryonic growth through accelerated segmentation and increased proliferation of mouse embryonic stem cell (mESC)‐induced presomitic ...
Gang Chen +11 more
wiley +1 more source
Isolated Nonischemic Left Bundle Branch Block Resulting in Heart Failure in Hodgkin Lymphoma Survivors Post-Radiation. [PDF]
Mangano CM +5 more
europepmc +1 more source
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun +23 more
wiley +1 more source

